This activity was originally presented at the 2024 ASHP Midyear Clinical Meeting & Exhibition.
Program Description
Bispecific antibodies (BsAbs) have an established efficacy profile in treating B-cell non-Hodgkin lymphoma (NHL). But beyond their therapeutic efficacy, BsAbs offer advantages such as fewer immune reactions when compared with CAR T-cell therapy. When utilized and incorporated into clinical practice appropriately, BsAbs have the potential to enhance safety and quality of life for patients with NHL. Each BsAb has unique pharmacological characteristics that may influence treatment decisions, including route of administration, duration of therapy, and monitoring requirements that oncology pharmacists must consider, as these differences can have a major impact on therapeutic decision-making, formulary decisions, and patients’ quality of life. This program will explore clinical strategies oncology pharmacists can implement into practice to improve safety and maintain outpatient treatment of BsAbs. Panelists will present case-based scenarios addressing common operational challenges in the use of BsAbs, discussing various pharmacist roles within the health system to improve safety and uptake of these therapies.
Target audience: Health-system pharmacists and oncology pharmacists
Type of activity: Application
Release date: December 13, 2024
Expiration date: December 13, 2025
Time to complete activity: 1.5 hours
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate clinical evidence of bispecific antibodies (BsAbs) in follicular and diffuse large B-cell lymphoma to guide evidence-based decision-making in clinical practice
- Explore clinical, operational, and pharmacological variances among BsAbs for non-Hodgkin lymphoma (NHL) to guide personalized treatment selection based on patient and disease factors
- Identify solutions to simplify care coordination for patients receiving outpatient BsAb treatment for NHL
- Employ strategies within various health-system settings to improve safe use of BsAbs in NHL
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
